234 related articles for article (PubMed ID: 16774555)
1. Anti-cytomegalovirus prophylaxis in solid-organ transplant recipients.
Falagas ME; Vardakas KZ
Clin Microbiol Infect; 2006 Jul; 12(7):603-5. PubMed ID: 16774555
[TBL] [Abstract][Full Text] [Related]
2. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
Hodson EM; Ladhani M; Webster AC; Strippoli GF; Craig JC
Cochrane Database Syst Rev; 2013 Feb; (2):CD003774. PubMed ID: 23450543
[TBL] [Abstract][Full Text] [Related]
3. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
Hodson EM; Barclay PG; Craig JC; Jones C; Kable K; Strippoli GF; Vimalachandra D; Webster AC
Cochrane Database Syst Rev; 2005 Oct; (4):CD003774. PubMed ID: 16235341
[TBL] [Abstract][Full Text] [Related]
4. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
Vernooij RW; Michael M; Ladhani M; Webster AC; Strippoli GF; Craig JC; Hodson EM
Cochrane Database Syst Rev; 2024 May; 5(5):CD003774. PubMed ID: 38700045
[TBL] [Abstract][Full Text] [Related]
5. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
Hodson EM; Craig JC; Strippoli GF; Webster AC
Cochrane Database Syst Rev; 2008 Apr; (2):CD003774. PubMed ID: 18425894
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.
Reischig T; Hribova P; Jindra P; Hes O; Bouda M; Treska V; Viklicky O
J Am Soc Nephrol; 2012 Sep; 23(9):1588-97. PubMed ID: 22917575
[TBL] [Abstract][Full Text] [Related]
7. Advances in cytomegalovirus-preventive strategies in solid organ transplantation: defending pre-emptive therapy.
Reischig T
Expert Rev Anti Infect Ther; 2012 Jan; 10(1):51-61. PubMed ID: 22149614
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and cost-effectiveness of valacyclovir in cytomegalovirus prevention in solid organ transplantation.
Reischig T; Kacer M
Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):771-9. PubMed ID: 25252996
[TBL] [Abstract][Full Text] [Related]
9. Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients.
Reischig T; Nemcová J; Vanecek T; Jindra P; Hes O; Bouda M; Treska V
Antivir Ther; 2010; 15(1):23-30. PubMed ID: 20167988
[TBL] [Abstract][Full Text] [Related]
10. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials.
Hodson EM; Jones CA; Webster AC; Strippoli GF; Barclay PG; Kable K; Vimalachandra D; Craig JC
Lancet; 2005 Jun 18-24; 365(9477):2105-15. PubMed ID: 15964447
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of pre-emptive or prophylactic valganciclovir therapy for prevention of cytomegalovirus infection in renal transplantation.
Santos RD; Brennan DC
J Am Soc Nephrol; 2012 Sep; 23(9):1446-8. PubMed ID: 22878958
[No Abstract] [Full Text] [Related]
12. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy.
Kalil AC; Freifeld AG; Lyden ER; Stoner JA
PLoS One; 2009; 4(5):e5512. PubMed ID: 19436751
[TBL] [Abstract][Full Text] [Related]
13. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients.
Torres-Madriz G; Boucher HW
Clin Infect Dis; 2008 Sep; 47(5):702-11. PubMed ID: 18652557
[TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus prophylaxis in pediatric kidney transplantation: the Dutch experience.
Jongsma H; Bouts AH; Cornelissen EA; Beersma MF; Cransberg K
Pediatr Transplant; 2013 Sep; 17(6):510-7. PubMed ID: 23890076
[TBL] [Abstract][Full Text] [Related]
15. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation.
Winston DJ; Yeager AM; Chandrasekar PH; Snydman DR; Petersen FB; Territo MC;
Clin Infect Dis; 2003 Mar; 36(6):749-58. PubMed ID: 12627359
[TBL] [Abstract][Full Text] [Related]
16. Valacyclovir or valganciclovir for cytomegalovirus prophylaxis: A randomized controlled trial in adult and pediatric kidney transplant recipients.
Verghese PS; Evans MD; Hanson A; Hathi J; Chinnakotla S; Matas A; Balfour HH
J Clin Virol; 2024 Jun; 172():105678. PubMed ID: 38688164
[TBL] [Abstract][Full Text] [Related]
17. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation.
Reischig T; Jindra P; Hes O; Svecová M; Klaboch J; Treska V
Am J Transplant; 2008 Jan; 8(1):69-77. PubMed ID: 17973956
[TBL] [Abstract][Full Text] [Related]
18. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients.
Strippoli GF; Hodson EM; Jones CJ; Craig JC
Cochrane Database Syst Rev; 2006 Jan; (1):CD005133. PubMed ID: 16437521
[TBL] [Abstract][Full Text] [Related]
19. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients.
Owers DS; Webster AC; Strippoli GF; Kable K; Hodson EM
Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD005133. PubMed ID: 23450558
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus prophylaxis in solid organ transplantation.
Alexopoulos SP; Lindberg L; Subramanyan RK; Matsuoka L
Curr Med Chem; 2012; 19(35):5957-63. PubMed ID: 22963558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]